Rosuvastatin and ezetimibe for the treatment of dyslipidemia and hypercholesterolemia.

Expert Review of Cardiovascular Therapy
Chrysoula BoutariVasilios G Athyros

Abstract

Introduction: Statins are powerful lipid-lowering agents which reduce cardiovascular (CV)-related morbidity and mortality. However, a large proportion of patients cannot attain the target low-density lipoprotein cholesterol (LDL-C) levels, despite receiving maximally tolerated doses of high-intensity statins. Also, adherence to treatment may be reduced due to statin-induced myopathy or other side effects. For these reasons, guidelines recommend adding the cholesterol absorption inhibitor ezetimibe.Areas covered: Authors discuss the main pharmacological characteristics of rosuvastatin and ezetimibe, their lipid-lowering and pleiotropic effects, as well as the clinical effects of the fixed dose combination of these drugs when used to treat dyslipidemia.Expert opinion: The rosuvastatin/ezetimibe combination is safe and effective in patients with hypercholesterolemia or dyslipidemia with or without diabetes and with or without cardiovascular disease. This drug combination enabled higher proportions of patients to achieve recommended LDL-C goals than rosuvastatin monotherapy or the simvastatin/ezetimibe combination, without additional adverse events. Despite the lack of additional CV outcomes data and comparisons with atorvastatin/e...Continue Reading

References

Aug 3, 2002·Journal of Acquired Immune Deficiency Syndromes : JAIDS·Daniel KleinStephen Sidney
Jul 16, 2003·The American Journal of Cardiology·Peter H JonesUNKNOWN STELLAR Study Group
Oct 29, 2003·Nature Reviews. Drug Discovery·Jeremy QuirkPeter Kirkpatrick
Nov 6, 2003·AIDS·Murielle Mary-KrauseUNKNOWN Clinical Epidemiology Group from the French Hospital Database
Jun 15, 2007·Lipids in Health and Disease·Matthew T BennettGregory P Bondy
Jul 31, 2007·Current Medical Research and Opinion·D P MikhailidisA L Catapano
Feb 10, 2009·Current Pharmaceutical Design·Vasilios G AthyrosDimitri P Mikhailidis
Feb 13, 2009·Current Medical Research and Opinion·Konstantinos TziomalosDimitri P Mikhailidis
Feb 19, 2009·International Journal of Clinical Practice·M RizzoN K Kapur
Nov 26, 2010·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·Pedro Plans-Rubió
Jan 11, 2011·Journal of Vascular Surgery·Kosmas I ParaskevasFrank J Veith
May 11, 2012·Journal of Cardiovascular Pharmacology and Therapeutics·George N KouvelosHaralampos J Milionis
Jan 16, 2013·Current Pharmaceutical Design·Niki KatsikiDimitri P Mikhailidis
Jun 6, 2013·Nature Reviews. Cardiology·Željko Reiner
Jan 8, 2015·Current Medical Research and Opinion·Aris P Agouridis, Dimitri P Mikhailidis
Feb 18, 2015·European Journal of Preventive Cardiology·Kornelia KotsevaUNKNOWN on behalf of the EUROASPIRE Investigators
Jun 4, 2015·The New England Journal of Medicine·Christopher P CannonUNKNOWN IMPROVE-IT Investigators
Dec 13, 2016·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·António Miguel Ferreira, Pedro Marques da Silva
Dec 23, 2016·Clinical Therapeutics·Young-June YangYangsoo Jang
Feb 17, 2017·Therapeutic Advances in Chronic Disease·Daniel Hammersley, Mark Signy
Sep 19, 2017·Expert Opinion on Drug Metabolism & Toxicology·Marilisa BoveArrigo F G Cicero
Nov 23, 2017·International Journal of Clinical Pharmacology and Therapeutics·Woo Youl KangHae Won Lee
Sep 11, 2019·European Heart Journal·François MachUNKNOWN ESC Scientific Document Group
Feb 11, 2020·Expert Opinion on Pharmacotherapy·Larysa StrilchukArrigo F G Cicero
Feb 20, 2021·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Maciej BanachUNKNOWN ACS EuroPath Central & South European Countries Project

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.

Cardiovascular Disorder in Diabetes

Diabetes is associated with an increased risk of cardiovascular disorders and heart failure. Discover the latest research here.

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.